AVOS Therapeutic Market Outlooks
What are Therapeutic Market Outlooks?
Therapeutic Market Outlook (TMO) reports are a regularly updated "deep dive" on U.S. therapeutic markets for the most dynamic disease states. Each report delivers a seven-year, patient-based U.S. revenue forecast at the level of the product (inline and pipeline), the therapeutic class, and the overall disease market. TMO reports combine a marketing executive's perspective on the salient factors influencing a product's uptake and use with the rigorously metrical perspective of a capital market analyst.
Our market models are systematic and consistent across all therapeutic areas. We develop them from a wide range of primary and secondary sources, including:
- Portfolio performance data from proprietary AVOS databases
- Physician panels (views, practices, and intentions) presented as interviews, surveys, conjoints
- Worldwide product revenues based on consensus sell-side analyst forecasts
- Unit volume, retail and list pricing, prescription data, and pipeline data from a variety of commercial databases
- AVOS's proprietary 10-year patient population model (theoretical, addressable, treated, and compliant populations)
AVOS's established network of high-prescribing and thought-leading physicians provides product opinions, a window into current prescribing practices and emerging shifts in market share, reactions to regulatory and market events, and future prescribing intentions. Their insights are supplemented by AVOS' senior staff which bring an aggregate of 70 years of brand management, business development, managed care, new product planning, and equity research experience.
TMO data and analysis is presented in clear language and easy-to-scan charts and at a level of detail that speaks directly to the information needs of R&D, marketing and business development professionals.
The following reports are available
| Multiple Sclerosis | July 11, 2008 |
| Insomnia | January 15, 2008 |
| Obesity | December 15, 2007 |
| Asthma/COPD | November 15, 2007 |
| Diabetes | October 15, 2007 |
| Depression | August 31, 2007 |
| Lipid Modulating Agents | July 31, 2007 |
Pricing and Deliverables for TMO Reports
| Type of Purchase | Type of Deliverable - Price ($USD) | ||
|---|---|---|---|
| Individual Title | Print Copy - $5,000 | Single Site License PDF - $7,000 | Global License PDF - $9,995 |
| Multiple Titles (3 or more) | Print Copy - $4,000/unit | Single Site License PDF - $5,500/unit | Global License PDF - $8,000/unit |
| Subscription (all 7 titles) | Only available as global license - call Mike Goodman at 919-475-9695 for details. Subscription clients receive 8 hours inquiry time with the author; an update of each title at time of purchase and ongoing event-driven updates for a period of 12 months; and 3 complimentary market models which our analysts will run around an event or assumption of your choosing. | ||
| Custom Projects | AVOS will undertake custom TMO projects focused on a primary care or specialty disease indication of your choice. We promise a standard 8-week turnaround for a US-focused TMO, and a standard 10-week turnaround for a global TMO (US, UK, Germany). For more information, or to discuss faster turnaround times on custom TMO projects, contact Mike Goodman at 919-475-9695 or reports@avoslifesciences.com. AVOS also offers 72 hour turnaround on custom physician research projects. | ||
| Updates | Purchasers of TMOs (single-site license or global license) will receive event-driven updates for a period of 12-months from purchase. Each update will include a revised market model (per product, per class, and per overall disease market) and a page summarizing the qualitative and quantitative impacts of the event. Reasons for updates include events not foreseen by the published report, such as product withdrawals or pipeline failures that would have a substantial impact on the AVOS forecast model. | ||
| Print copies are hard copies that do not permit electronic sharing, searching, or cutting and pasting Single site license PDF is an electronic copy that may be shared at an address (e.g., Roche in Palo Alto) Global license PDF may be shared across the global enterprise, including all affiliates and subsidiaries |
|||
July 2008 TMO MS Report
In July 2008, AVOS published an updated and improved TMO Multiple Sclerosis Report. Among several other changes, the update included the use of more robust and comprehensive modeling techniques leading to improved forecasting of the market. View more information about the July 2008 TMO Multiple Sclerosis Report.
